Target Identification

Start by clearly defining the disease of interest, its known pathophysiology, and the biological hypothesis (e.g., gain-of-function mutation, pathway dysregulation). Review literature, public databases (e.g., OMIM, GWAS Catalog), and prior target-disease associations to frame the search space. This step ensures all downstream analysis is anchored to a clinically meaningful question.

Why Causaly: Causaly is specifically designed for target identification and disease pathophysiology deciphering, directly matching the step's need to define disease context and biological hypothesis using literature and genomic databases.

Collect relevant genomic, transcriptomic, proteomic, or epigenomic datasets from public repositories (e.g., TCGA, GEO, ENCODE) or proprietary sources. Perform quality control, normalization, and batch correction to ensure data integrity. This step transforms raw data into a clean, analysis-ready matrix.

Why BERG (BPGbio): BERG (BPGbio) explicitly supports target identification and biomarker discovery, which aligns with acquiring and preprocessing multi-omics data for downstream analysis.

Run differential expression, mutation burden, or copy number variation analyses to identify genes or variants significantly altered in disease vs. control. Integrate multiple omics layers (e.g., RNA-seq + proteomics) using statistical or machine learning methods (e.g., MOFA, mixOmics) to pinpoint consistently dysregulated candidates. Filter results by effect size and statistical significance.

Why Recursion OS: Recursion OS is built for target identification and predictive modeling, directly applicable to performing differential and integrative analysis of multi-omics data.

Filter the candidate list using functional annotations (e.g., gene essentiality, pathway membership, protein-protein interactions) and druggability criteria (e.g., presence of a binding pocket, known drug-like ligands). Use tools like Open Targets, DrugBank, and ChEMBL to score each candidate on tractability and safety. Retain only targets with high confidence in both disease relevance and therapeutic potential.

Why Causaly: Causaly's target identification and disease pathophysiology capabilities support functional and druggability filtering by integrating knowledge from databases like Open Targets and DrugBank.

Stratify patient cohorts (e.g., from TCGA or clinical trial data) based on target expression or mutation status. Perform survival analysis (Kaplan-Meier, Cox regression) and correlation with clinical outcomes (e.g., drug response, progression-free survival). This step confirms that the target is clinically relevant and not just statistically significant.

Why BERG (BPGbio): BERG (BPGbio) explicitly includes patient stratification for clinical trials, directly matching the need to validate targets using clinical data and survival analysis.

Synthesize all findings into a structured report that includes the hypothesis, data sources, analysis methods, prioritized target list, cohort validation results, and recommended next steps (e.g., in vitro validation, assay development). Provide visual summaries (volcano plots, forest plots, cohort survival curves) and a decision matrix for stakeholders. This is the final deliverable for decision-making.

Why AIPRM for ChatGPT (Presentation Workflows): AIPRM for ChatGPT (Presentation Workflows) is designed for slide-by-slide outlining and markdown presentation formatting, directly supporting the compilation and delivery of a target identification report.